Background Sulfonylurea drugs have been the only oral therapyavailable for patients with non-insulin-dependent diabetes mellitus(NIDDM) in the United States. Recently, however, metformin hasbeen approved for the treatment of NIDDM.
Methods We performed two large, randomized, parallel-group,double-blind, controlled studies in which metformin or anothertreatment was given for 29 weeks to moderately obese patientswith NIDDM whose diabetes was inadequately controlled by diet(protocol 1: metformin vs. placebo; 289 patients), or diet plusglyburide (protocol 2: metformin and glyburide vs. metforminvs. glyburide; 632 patients). To determine efficacy we measuredplasma glucose (while the patients were fasting and after theoral administration of glucose), lactate, lipids, insulin, andglycosylated hemoglobin before, during, and at the end of thestudy.
Results In protocol 1, at the end of the study the 143 patientsin the metformin group, as compared with the 146 patients inthe placebo group, had lower mean (±SE) fasting plasmaglucose concentrations (189±5 vs. 244±6 mg perdeciliter [10.6±0.3 vs. 13.7±0.3 mmol per liter],P<0.001) and glycosylated hemoglobin values (7.1±0.1percent vs. 8.6±0.2 percent, P<0.001). In protocol2, the 213 patients given metformin and glyburide, as comparedwith the 209 patients treated with glyburide alone, had lowermean fasting plasma glucose concentrations (187±4 vs.261±4 mg per deciliter [10.5±0.2 vs. 14.6±0.2mmol per liter], P<0.001) and glycosylated hemoglobin values(7.1±0.1 percent vs. 8.7±0.1 percent, P<0.001).The effect of metformin alone was similar to that of glyburidealone. Eighteen percent of the patients given metformin andglyburide had symptoms compatible with hypoglycemia, as comparedwith 3 percent in the glyburide group and 2 percent in the metformingroup.
In both protocols the patients given metformin had statisticallysignificant decreases in plasma total and low-density lipoproteincholesterol and triglyceride concentrations, whereas the valuesin the respective control groups did not change. There wereno significant changes in fasting plasma lactate concentrationsin any of the groups.
Conclusions Metformin monotherapy and combination therapy withmetformin and sulfonylurea are well tolerated and improve glycemiccontrol and lipid concentrations in patients with NIDDM whosediabetes is poorly controlled with diet or sulfonylurea therapyalone.
Source Information
From the Diabetes Division, University of Texas Health Science Center, San Antonio (R.A.D.), and Lipha Pharmaceuticals, New York (A.M.G.).
Address reprint requests to Dr. DeFronzo at the Diabetes Division, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284.
Pflipsen, M. C., Oh, R. C., Saguil, A., Seehusen, D. A., Topolski, R.
(2009). The Prevalence of Vitamin B12 Deficiency in Patients with Type 2 Diabetes: A Cross-Sectional Study. J Am Board Fam Med
22: 528-534
[Abstract][Full Text]
Crandall, J. P, Polsky, S., Howard, A. A, Perreault, L., Bray, G. A, Barrett-Connor, E., Brown-Friday, J., Whittington, T., Foo, S., Ma, Y., Edelstein, S. L, for the Diabetes Prevention Program Research Group,
(2009). Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am. J. Clin. Nutr.
90: 595-601
[Abstract][Full Text]
Wilding, J.
(2009). Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. British Journal of Diabetes & Vascular Disease
9: 177-185
[Abstract]
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S.F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N.A., Pearson, E. R.
(2009). Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study. Diabetes
58: 1434-1439
[Abstract][Full Text]
DeFronzo, R. A.
(2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes
58: 773-795
[Full Text]
Havas, S.
(2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med
169: 150-154
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin. Diabetes
27: 4-16
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Spectr.
22: 6-17
[Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care
32: 193-203
[Abstract][Full Text]
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., Brancati, F. L.
(2008). Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review. Arch Intern Med
168: 2070-2080
[Abstract][Full Text]
Scarpello, J. H., Howlett, H. C.
(2008). Metformin therapy and clinical uses. Diabetes and Vascular Disease Research
5: 157-167
[Abstract]
Hong, Y., Rohatagi, S., Habtemariam, B., Walker, J. R., Schwartz, S. L., Mager, D. E.
(2008). Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. J Clin Pharmacol
48: 696-707
[Abstract][Full Text]
Kim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., Lee, C.-H., Choi, H.-S.
(2008). Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP. Diabetes
57: 306-314
[Abstract][Full Text]
Fowler, M. J.
(2007). Diabetes Treatment, Part 2: Oral Agents for Glycemic Management. Clin. Diabetes
25: 131-134
[Full Text]
Hollander, P.
(2007). Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes. Diabetes Spectr.
20: 159-165
[Abstract][Full Text]
Blonde, L.
(2007). Easing the Transition to Insulin Therapy in People With Type 2 Diabetes. The Diabetes Educator
33: 232S-240S
[Full Text]
Gottschalk, M., Danne, T., Vlajnic, A., Cara, J. F.
(2007). Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes: A randomized, single-blind comparative study. Diabetes Care
30: 790-794
[Abstract][Full Text]
Abrahamson, M. J.
(2007). A 74-Year-Old Woman With Diabetes. JAMA
297: 196-204
[Abstract][Full Text]
Duncan, A. I., Koch, C. G., Xu, M., Manlapaz, M., Batdorf, B., Pitas, G., Starr, N.
(2007). Recent Metformin Ingestion Does Not Increase In-Hospital Morbidity or Mortality After Cardiac Surgery. Anesth. Analg.
104: 42-50
[Abstract][Full Text]
Heine, R J, Diamant, M, Mbanya, J-C, Nathan, D M
(2006). Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?. BMJ
333: 1200-1204
[Full Text]
Skaer, T. L., Sclar, D. A., Robison, L. M.
(2006). Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation?. The Diabetes Educator
32: 940-953
[Abstract][Full Text]
Ong, C. R., Molyneaux, L. M., Constantino, M. I., Twigg, S. M., Yue, D. K.
(2006). Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.. Diabetes Care
29: 2361-2364
[Abstract][Full Text]
Triplitt, C., Glass, L., Miyazaki, Y., Wajcberg, E., Gastaldelli, A., De Filippis, E., Cersosimo, E., DeFronzo, R. A.
(2006). Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.. Diabetes Care
29: 2371-2377
[Abstract][Full Text]
Ting, R. Z.-W., Szeto, C. C., Chan, M. H.-M., Ma, K. K., Chow, K. M.
(2006). Risk factors of vitamin B12 deficiency in patients receiving metformin.. Arch Intern Med
166: 1975-1979
[Abstract][Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., Zinman, B.
(2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care
29: 1963-1972
[Full Text]
Mooradian, A. D., Bernbaum, M., Albert, S. G.
(2006). Narrative Review: A Rational Approach to Starting Insulin Therapy. ANN INTERN MED
145: 125-134
[Abstract][Full Text]
Barnett, A. H., Dreyer, M., Lange, P., Serdarevic-Pehar, M., on behalf of the Exubera Phase III Study Group,
(2006). An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea.. Diabetes Care
29: 1282-1287
[Abstract][Full Text]
Schwartz, S., Fonseca, V., Berner, B., Cramer, M., Chiang, Y.-K., Lewin, A.
(2006). Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes. Diabetes Care
29: 759-764
[Abstract][Full Text]
Bowker, S. L., Majumdar, S. R., Veugelers, P., Johnson, J. A.
(2006). Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care
29: 254-258
[Abstract][Full Text]
Schultes, B., Peters, A., Hallschmid, M., Benedict, C., Merl, V., Oltmanns, K. M., Born, J., Fehm, H. L., Kern, W.
(2005). Modulation of Food Intake by Glucose in Patients With Type 2 Diabetes. Diabetes Care
28: 2884-2889
[Abstract][Full Text]
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., Johnson, J. A.
(2005). Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure. Diabetes Care
28: 2345-2351
[Abstract][Full Text]
Misbin, R. I.
(2005). Evaluating the Safety of Diabetes Drugs: Perspective of a Food and Drug Administration insider. Diabetes Care
28: 2573-2576
[Full Text]
Fantus, I. G.
(2005). Metformin's contraindications: needed for now. CMAJ
173: 505-507
[Full Text]
Eddy, D. M., Schlessinger, L., Kahn, R.
(2005). Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. ANN INTERN MED
143: 251-264
[Abstract][Full Text]
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D.
(2005). Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care
28: 1092-1100
[Abstract][Full Text]
Karlsson, H. K.R., Hallsten, K., Bjornholm, M., Tsuchida, H., Chibalin, A. V., Virtanen, K. A., Heinonen, O. J., Lonnqvist, F., Nuutila, P., Zierath, J. R.
(2005). Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study. Diabetes
54: 1459-1467
[Abstract][Full Text]
Kimmel, B., Inzucchi, S. E.
(2005). Oral Agents for Type 2 Diabetes: An Update. Clin. Diabetes
23: 64-76
[Abstract][Full Text]
Yale, J.-F.
(2005). Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts. J. Am. Soc. Nephrol.
16: S7-S10
[Abstract][Full Text]
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., Krumholz, H. M.
(2005). Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. Circulation
111: 583-590
[Abstract][Full Text]
Rautio, K, Tapanainen, J S, Ruokonen, A, Morin-Papunen, L C
(2005). Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol
152: 269-275
[Abstract][Full Text]
Miyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J, Defronzo, R. A
(2005). Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. British Journal of Diabetes & Vascular Disease
5: 28-35
[Abstract]
Schernthaner, G., Matthews, D. R., Charbonnel, B., Hanefeld, M., Brunetti, P., on Behalf of the Quarter Study Group,
(2004). Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial. J. Clin. Endocrinol. Metab.
89: 6068-6076
[Abstract][Full Text]
Klein, J., Westphal, S., Kraus, D., Meier, B., Perwitz, N., Ott, V., Fasshauer, M., Klein, H H.
(2004). Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J Endocrinol
183: 299-307
[Abstract][Full Text]
Sparre Hermann, L., Nilsson, B., Wettre, S.
(2004). Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. British Journal of Diabetes & Vascular Disease
4: 401-406
[Abstract]
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., for the Exenatide-113 Clinical Study Group,
(2004). Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. Diabetes Care
27: 2628-2635
[Abstract][Full Text]
Adediran, I A, Ikem, R T, Borisade, M F
(2004). Fibrinolytic activity in Nigerian diabetics. Postgrad. Med. J.
80: 610-612
[Abstract][Full Text]
Yki-Jarvinen, H.
(2004). Thiazolidinediones. NEJM
351: 1106-1118
[Full Text]
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., Kim, C., Lau, J.
(2004). Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus: A Meta-analysis. Arch Intern Med
164: 1395-1404
[Abstract][Full Text]
Davidson, J., Howlett, H.
(2004). New prolonged-release metformin improves gastrointestinal tolerability. British Journal of Diabetes & Vascular Disease
4: 273-277
[Abstract]
Misbin, R. I.
(2004). The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes. Diabetes Care
27: 1791-1793
[Full Text]
Leclerc, I., Woltersdorf, W. W., da Silva Xavier, G., Rowe, R. L., Cross, S. E., Korbutt, G. S., Rajotte, R. V., Smith, R., Rutter, G. A.
(2004). Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab.
286: E1023-E1031
[Abstract][Full Text]
Hanefeld, M., Brunetti, P., Schernthaner, G. H., Matthews, D. R., Charbonnel, B. H.
(2004). One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care
27: 141-147
[Abstract][Full Text]
Salpeter, S. R., Greyber, E., Pasternak, G. A., Salpeter, E. E.
(2003). Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med
163: 2594-2602
[Abstract][Full Text]
Eddy, D. M., Schlessinger, L.
(2003). Archimedes: A trial-validated model of diabetes. Diabetes Care
26: 3093-3101
[Abstract][Full Text]
De Leo, V., la Marca, A., Petraglia, F.
(2003). Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. Endocr. Rev.
24: 633-667
[Abstract][Full Text]
Gahagan, S., Silverstein, J., Committee on Native American Child Health, , Section on Endocrinology,
(2003). Prevention and Treatment of Type 2 Diabetes Mellitus in Children, With Special Emphasis on American Indian and Alaska Native Children. Pediatrics
112: e328-e328
[Abstract][Full Text]
Garber, A. J., Donovan, D. S. Jr., Dandona, P., Bruce, S., Park, J.-S.
(2003). Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes. J. Clin. Endocrinol. Metab.
88: 3598-3604
[Abstract][Full Text]
Sheehan, M. T.
(2003). Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach. Clin Med Res
1: 189-200
[Abstract][Full Text]
Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., Festa, A., Tan, M. H.
(2003). Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab.
88: 1637-1645
[Abstract][Full Text]
Chan, J. L., Abrahamson, M. J.
(2003). Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin. Mayo Clin Proc.
78: 459-467
[Abstract]
Zangeneh, F., Kudva, Y. C., Basu, A.
(2003). Insulin Sensitizers. Mayo Clin Proc.
78: 471-479
[Abstract]
Schultes, B., Oltmanns, K. M., Kern, W., Fehm, H. L., Born, J., Peters, A.
(2003). Modulation of Hunger by Plasma Glucose and Metformin. J. Clin. Endocrinol. Metab.
88: 1133-1141
[Abstract][Full Text]
Gunton, J. E., Delhanty, P. J. D., Takahashi, S.-I., Baxter, R. C.
(2003). Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2. J. Clin. Endocrinol. Metab.
88: 1323-1332
[Abstract][Full Text]
Phillips, P., Karrasch, J., Scott, R., Wilson, D., Moses, R.
(2003). Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin. Diabetes Care
26: 269-273
[Abstract][Full Text]
Morin-Papunen, L., Vauhkonen, I., Koivunen, R., Ruokonen, A., Martikainen, H., Tapanainen, J. S.
(2003). Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study. J. Clin. Endocrinol. Metab.
88: 148-156
[Abstract][Full Text]
Sasali, A., Leahy, J. L.
(2003). Is Metformin Cardioprotective?. Diabetes Care
26: 243-244
[Full Text]
Defronzo, R. A
(2003). Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?. British Journal of Diabetes & Vascular Disease
3: S24-S40
[Abstract]
Wulffele, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., Borger van der Burg, B., Donker, A. J.M., Stehouwer, C. D.A.
(2002). Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes. Diabetes Care
25: 2133-2140
[Abstract][Full Text]
Johnson, J. A., Majumdar, S. R., Simpson, S. H., Toth, E. L.
(2002). Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes. Diabetes Care
25: 2244-2248
[Abstract][Full Text]
Gastaldelli, A., Miyazaki, Y., Pettiti, M., Matsuda, M., Mahankali, S., Santini, E., DeFronzo, R. A., Ferrannini, E.
(2002). Metabolic Effects of Visceral Fat Accumulation in Type 2 Diabetes. J. Clin. Endocrinol. Metab.
87: 5098-5103
[Abstract][Full Text]
Nathan, D. M.
(2002). Initial Management of Glycemia in Type 2 Diabetes Mellitus. NEJM
347: 1342-1349
[Full Text]
Hadigan, C., Rabe, J., Grinspoon, S.
(2002). Sustained Benefits of Metformin Therapy on Markers of Cardiovascular Risk in Human Immunodeficiency Virus-Infected Patients with Fat Redistribution and Insulin Resistance. J. Clin. Endocrinol. Metab.
87: 4611-4615
[Abstract][Full Text]
Strowig, S. M., Aviles-Santa, M. L., Raskin, P.
(2002). Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes. Diabetes Care
25: 1691-1698
[Abstract][Full Text]
Bloomgarden, Z. T.
(2002). Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002. Diabetes Care
25: 1644-1649
[Full Text]
Kirpichnikov, D., McFarlane, S. I., Sowers, J. R.
(2002). Metformin: An Update. ANN INTERN MED
137: 25-33
[Abstract][Full Text]
Reasner, C. A, Goke, B.
(2002). Overcoming the barriers to effective glycaemic control for type 2 diabetes. British Journal of Diabetes & Vascular Disease
2: 290-295
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., Klein, S.
(2002). Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin. Diabetes Care
25: 1123-1128
[Abstract][Full Text]
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., DeFronzo, R. A.
(2002). Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients. J. Clin. Endocrinol. Metab.
87: 2784-2791
[Abstract][Full Text]
Miyazaki, Y., Matsuda, M., DeFronzo, R. A.
(2002). Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes. Diabetes Care
25: 517-523
[Abstract][Full Text]
Chu, N. V., Kong, A. P. S., Kim, D. D., Armstrong, D., Baxi, S., Deutsch, R., Caulfield, M., Mudaliar, S. R., Reitz, R., Henry, R. R., Reaven, P. D.
(2002). Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Diabetes Care
25: 542-549
[Abstract][Full Text]
Yanovski, S. Z., Yanovski, J. A.
(2002). Obesity. NEJM
346: 591-602
[Full Text]
Inzucchi, S. E.
(2002). Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review. JAMA
287: 360-372
[Abstract][Full Text]
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., Tomlinson, M. J.
(2002). Effect of Metformin in Pediatric Patients With Type 2 Diabetes: A randomized controlled trial. Diabetes Care
25: 89-94
[Abstract][Full Text]
White, J. R. Jr., Campbell, R. K.
(2001). Recent Developments in the Pharmacological Reduction of Blood Glucose in Patients With Type 2 Diabetes. Clin. Diabetes
19: 153-159
[Abstract][Full Text]
Fruehwald-Schultes, B., Kern, W., Oltmanns, K. M., Sopke, S., Toschek, B., Born, J., Fehm, H. L., Peters, A.
(2001). Metformin Does Not Adversely Affect Hormonal and Symptomatic Responses to Recurrent Hypoglycemia. J. Clin. Endocrinol. Metab.
86: 4187-4192
[Abstract][Full Text]
Pozzilli, P., Di Mario, U.
(2001). Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention. Diabetes Care
24: 1460-1467
[Abstract][Full Text]
Chiasson, J.-L., Naditch, L.
(2001). The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes. Diabetes Care
24: 989-994
[Abstract][Full Text]
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., DeFronzo, R. A.
(2001). Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone. Diabetes Care
24: 710-719
[Abstract][Full Text]
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., Holst, J. J.
(2001). Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes. Diabetes Care
24: 720-725
[Abstract][Full Text]
Matthaei, S., Stumvoll, M., Kellerer, M., Häring, H.-U.
(2000). Pathophysiology and Pharmacological Treatment of Insulin Resistance. Endocr. Rev.
21: 585-618
[Abstract][Full Text]
Morin-Papunen, L. C., Vauhkonen, I., Koivunen, R. M., Ruokonen, A., Martikainen, H. K., Tapanainen, J. S.
(2000). Endocrine and Metabolic Effects of Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study. J. Clin. Endocrinol. Metab.
85: 3161-3168
[Abstract][Full Text]
Campbell, S.
(2000). Management of Type 2 Diabetes in the Geriatric Patient. Journal of Pharmacy Practice
13: 263-276
[Abstract]
McAnulty, G. R., Robertshaw, H. J., Hall, G. M.
(2000). Anaesthetic management of patients with diabetes mellitus. Br J Anaesth
85: 80-90
[Full Text]
DeFronzo, R. A.
(1999). Pharmacologic Therapy for Type 2 Diabetes Mellitus. ANN INTERN MED
131: 281-303
[Abstract][Full Text]
Aviles-Santa, L., Sinding, J., Raskin, P.
(1999). Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED
131: 182-188
[Abstract][Full Text]
Sclar, D. A., Robison, L. M., Skaer, T. L., Dickson, W. M., Kozma, C. M., Reeder, C. E.
(1999). Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race. The Diabetes Educator
25: 531-538
Yki-Jarvinen, H., Ryysy, L., Nikkila, K., Tulokas, T., Vanamo, R., Heikkila, M.
(1999). Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. ANN INTERN MED
130: 389-396
[Abstract][Full Text]
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., Shulman, G. I.
(1998). Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. NEJM
338: 867-873
[Abstract][Full Text]
Stern, M. P.
(1998). The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes. Arch Fam Med
7: 155-162
[Abstract][Full Text]
Previous
